{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-073386","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.278821+00:00","generated_at":"2026-05-15T23:45:23.313173+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kymera reports FY2025 net loss $311M; cash $1.6B; STAT6 and IRF5 trials advancing","bullets":["Cash and investments of $1.6B as of Dec 31, 2025, providing runway into 2029.","KT-621 (STAT6) Phase 2b in atopic dermatitis (enrollment ongoing) and asthma (dosing started); data expected mid- and late-2027.","KT-579 (IRF5) Phase 1 healthy volunteer trial dosed; data expected in 2H26.","Appointed Dr. Neil Graham as Chief Development Officer; he led dupilumab development at Regeneron.","FY2025 collaboration revenue $39.2M, R&D expense $316.6M, net loss $311.4M (vs. $223.9M in FY2024)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-073386","json":"https://secwatch.observer/filing/0001193125-26-073386.json","markdown":"https://secwatch.observer/filing/0001193125-26-073386.md","text":"https://secwatch.observer/filing/0001193125-26-073386.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526073386/0001193125-26-073386-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526073386/kymr-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:45:23.313173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}